Beta Drugs Limited (BETA)
Updates
H1FY27 results (unaudited):
Consolidated:
Revenue 2.63bn +29% y-y (2.04bn)
EBITDA 0.61bn +30% y-y (0.47bn)
EBITDA margin 23.2% (23.1%) +10 bps y-y
PAT 0.34bn +43% y-y (0.24bn)
Standalone:
Revenue 1.04bn +16% y-y (0.90bn)
EBITDA 0.29bn +22% y-y (0.24bn) [derived]
EBITDA margin 27.9% (26.7%) +120 bps y-y
PAT 0.10bn +33% y-y (0.08bn)
Dividend: None stated
Commentary: Company expects FY27 consolidated revenue above 5.35bn with EBITDA margin 23%-24%, driven by strong growth in branded oncology, CMO, exports, and Nivian lifesciences; backward integration and capacity expansion underway to support margin improvement and regulatory compliance.
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 BETA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add BETA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Beta Drugs Limited
Important.
The summary above is generated automatically from Beta Drugs Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.